

Provider Toolkit

Updated April 2021

Contents

- Background
- Provider Resources
- Patient Resources



Background

- This toolkit provides Maryland health care professionals with resources and information on monoclonal antibody treatment for COVID-19.
- Monoclonal antibody treatment (mAb) is not a cure, but it may lessen symptom severity and help keep high-risk patients out of the hospital.



What is Monoclonal Antibody Treatment

- When you are sick, your body makes antibodies on its own to fight the illness.
- Monoclonal antibodies are laboratory-made proteins that mimic natural antibodies' ability to fight viruses, such as COVID-19.



Who Qualifies for Treatment

mAb treatment is for adults and adolescents (12-17 years old) with mild to moderate COVID-19 symptoms who:

- Recently tested positive for COVID-19
- Are within 10 days of first experiencing symptoms
- Do not need to be hospitalized for COVID-19
- Weigh at least 88 pounds



Who Qualifies for Treatment


continued

Are in one of the following high-risk categories:

- Are age 65 and older <u>OR</u> have chronic kidney disease, BMI of 35 or greater, diabetes, or an immunosuppressive disease
- Are age 55 to 64 <u>AND</u> have cardiovascular disease, hypertension, chronic respiratory diseases, or COPD
- For adolescents: high BMI, sickle cell disease, heart disease, neurodevelopmental disorders, a medical-related technological dependence, asthma or other chronic respiratory disease



Treatment Locations in Maryland



As of 4/2/21



Provider Resources



Provider Resources

Resources for Health Care Professional are available at <u>Information</u> <u>about Monoclonal Antibodies (mAb)</u>



Referral and Infusion Location Flyer

Health Care Provider referrals to Monoclonal Antibody Infusions • Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease mAbs are likely to be most beneficial if given to patients early in symptom • Product delivered via single IV infusion administration • Early evidence suggest promise of mAb products in outpatient settings to reduce hospitalization Process to refer your patients 1. Review patient eligibility criteria for patients with mild-moderate symptoms. following:

Full criteria listed by FDA:

Casirivimab and Imdevimab

complete this form if interested).

Bamlanivimab

Rapid Antigen Test

infusion site* ASAP

Send eReferral via the CRISP

Unified Landing Page


(Starter guide: pp. 1-7, 25-35)

*(Infusion sites listed on next page)

Page 1

Health Care Provider Referral to Monoclonal Antibody Infusion Overview and Location Flyer

Updated weekly with new site locations





Referral Options



Option 1:

CRISP eREFERRAL for Monoclonal Antibody Infusion

Access the CRISP mAb eREFERRAL Starter Guide



Referral Options



Option 2:

Maryland Referral Form for Monoclonal Antibody Infusion Treatment



Point-of-Care Rapid Antigen Testing

- Testing provided to practices willing to identify and refer symptomatic patients eligible for mAb therapy
- Interested practices should fill out this <u>Google Form</u> as soon as possible
- After filling out the form, Maryland Department of Health staff will contact you with next steps
- More information is available <u>here</u>



Federal Resources

- HHS COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
- HHS Therapeutics Distribution Locations
- •FDA clinical information about mAb therapeutics:
 - Fact Sheet for Health Care Providers Emergency Use
 Authorization (EUA) of REGEN-COV
 - OBamlanivimab EUA Letter of Authorization Reissue 02092021



Patient Resources



Patient Resources

- FAQs about Monoclonal Antibody Treatment for COVID-19
- Monoclonal Antibody Therapy (mAb) for Treating COVID-19 Fact
 Sheet
- COVID-19 Monoclonal Antibody Treatment for Older Adults in Nursing Homes
- COVID-19 Monoclonal Antibody Therapeutics
- Monoclonal Antibodies Infographic



Social Media - Twitter



don't delay, patients must receive this treatment within 10

Learn more at bit.ly/mAbTreatments

days of symptom onset.










COVID-19 Treatments

Reduce your risk of hospitalization



Social Media - Facebook





Questions

For more information about mAb, please contact:

Maryland Department of Health

Dr. Howard Haft howard.haft@maryland.gov

Dr. Aliya Jones <u>aliya.jones@maryland.gov</u>

Array Advisors

Clairanne Pesce
Clinician Assistance/Outreach for Monoclonal Antibodies
covid@array-advisors.com